PubChem is a database of chemical molecules and their activities against biological assays. The system is maintained by the National Center for Biotechnology Information (NCBI), a component of the National Library of Medicine, which is part of the United States National Institutes of Health (NIH). PubChem can be accessed for free through a web user interface. Millions of compound structures and descriptive datasets can be freely downloaded via FTP. PubChem contains substance descriptions and small molecules with fewer than 1000 atoms and 1000 bonds. More than 80 database vendors contribute to the growing PubChem database.
| Organization: | NCBI |
|---|---|
| Category: | Governmental Organizations |
| Website: | https://pubchem.ncbi.nlm.nih.gov/ |
July 13, 2018, The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox. Though the World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980, there have been longstanding concerns that smallpox could be used as a bioweapon.
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Zemdri (plazomicin) is used in adult patients with complex urinary tract infections (cUTI, including pyelonephritis) caused by certain Enterobacteriaceae bacterial infections with very limited or no treatment options. This drug is an intravenous infusion drug. , once a day.
June 25, 2018, The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana. It is also the first FDA approval of a drug for the treatment of patients with Dravet syndrome.
On June 13, the FDA approved moxidectin for the treatment of onchocerciasis (river blindness) in patients 12 years of age and older by oral administration of 8 mg per day (4 tablets of 2 mg tablets).
Onchocerciasis is the second leading cause of blindness in the world following trachoma, mossy dermatitis, subcutaneous nodules and visual impairment caused by parasitic nematodes parasitic on human skin, subcutaneous tissue and eyes. A parasitic disease characterized by river blindness or filariasis.
Rheumatoid arthritis is a chronic, prone to progressive arthritis that is very painful. Currently, TNF inhibitors are a common rheumatoid arthritis therapy, but about two-thirds of patients are unable to get clinical remission from the first treatment. And over time, a large number of patients are unable to maintain the efficacy of the drug. Therefore, these patients urgently need an innovative drug to alleviate the disease.
May 24, 2018, The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down phenylalanine (Phe), an amino acid present in protein-containing foods and high-intensity sweeteners used in a variety of foods and beverages. Palynziq is a novel enzyme therapy for adult PKU patients who have uncontrolled blood Phe concentrations on current treatment.
May 21, 2018, The U.S. Food and Drug Administration today approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.
May 17, 2018, The U.S. Food and Drug Administration today approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks.
